A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (776 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: intravenousmldosespressurepf
  Phrases that lowered it: healthyopen labelthe pharmacokineticsto investigateinvestigate the
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 15.6% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 385 (raises risk) · Sponsor's track record
• Responsible party: not given (raises risk) · Design
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 674 (raises risk) · Sponsor's track record
• Blinding: none (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: 55 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study To Investigate The Elimination Of PF-06273588 From The Body Following A Single Low Dose. NCT01408355 · started 2011 · scored riskier than 4% of active trials completed
• A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers NCT01002963 · started 2009 · scored riskier than 8% of active trials completed
• To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity NCT01165736 · started 2010 · scored riskier than 4% of active trials completed
• A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571. NCT04866225 · started 2021 · scored riskier than 3% of active trials completed
• Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects NCT03448172 · started 2018 · scored riskier than 3% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.